Last Price | 8.75 | Max Price | 8.75 |
Min Price | 8.75 | 1 Year return | 0.00 |
Sector | Health Care | Subsector | Health Care Eq. & Services |
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 40 | 2,019,627 | 0.00 % |
2020 | 44 | 2,170,562 | 0.00 % |
2021 | 51 | 2,404,921 | 0.00 % |
2022 | 76 | 2,645,840 | 0.00 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
No Records Found
No Records Found
Over the past year the company' stock lost around 51 percent. The period between August 2011 and August 2016 was a bad period for the investors. The stock lost around 5 percent. Sharps Compliance Corp's revenues between 2011 and 2015 were very fluctuating and moved between 21,79 million dollars and 30,9 million dollars. The net results between 2011 and 2015 were far from constant and fluctuated between -2,98 million dollars and 1,16 million dollars.
The core activities of Sharps Compliance Corp are in the pharmaceutical sector. The past 10 years the (international) industry gained at around 75 percent. As from 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.
The American company didn't pay out any dividends (in the past 5 years).
As per the end of 2015 the American company's balance sheet equaled 29,75 million dollars. 6,16 million dollars (20,71 percent of the total balance sheet) was financed by debt. The American company's price/earnings-ratio was 53. So the market valued the stock at 53 times the 2015' earnings per share. We could say that based on it's price/earnings-ratio and dividend yield the American stock can be seen as a growth stock.
At the end of 2015 the pharmaceutical company's market size (her number of outstanding share times the stock price) equaled around 130,59 million dollars. At the end of 2015 the American company had around 15,33 million stocks listed.
All Sharps Compliance Corp's financial reports are available here. More information about Sharps Compliance Corp can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
27
|
31
|
33
|
38
|
40
|
44
|
Costs |
26
|
30
|
33
|
39
|
41
|
44
|
Profit |
1
|
1
|
0
|
-1
|
-1
|
|
Margin of profit |
3.61
|
3.75
|
0.03
|
-3.38
|
-1.67
|
0.47
|
ROI |
4.38
|
4.92
|
0.04
|
-5.10
|
-2.66
|
0.80
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
22
|
24
|
24
|
25
|
25
|
26
|
Debt |
5
|
6
|
6
|
9
|
8
|
10
|
Total assets |
26
|
30
|
30
|
34
|
33
|
36
|
Solvency |
82.77
|
79.29
|
79.07
|
73.39
|
75.74
|
72.50
|
Cash |
14
|
15
|
12
|
5
|
5
|
5
|
Cashflow |
-1
|
2
|
1
|
-1
|
2
|
1
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
-0.14
|
0.35
|
0.19
|
-0.06
|
0.29
|
0.09
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
8.70
|
3.83
|
4.09
|
3.45
|
4.22
|
Eps |
0.07
|
0.0
|
-0.08
|
-0.04
|
0.01
|
Price/earnings-ratio |
124.29
|
0.0
|
-51.12
|
-86.25
|
875.00
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
1.53
|
1.54
|
1.58
|
1.57
|
1.62
|
Market to book |
0.18
|
0.40
|
0.39
|
0.45
|
0.19
|
Cashflow per stock |
0.14
|
0.08
|
-0.04
|
0.15
|
0.06
|
Stocks |
15
|
15
|
16
|
16
|
16
|
Market Cap |
133.84
|
59.15
|
65.47
|
55.48
|
141.20
|
Date
|
Price
|
---|---|
01 May 2024
|
8.75
|
22 Apr 2024
|
8.75
|
18 Apr 2024
|
8.75
|
17 Apr 2024
|
8.75
|
09 Apr 2024
|
8.75
|
05 Apr 2024
|
8.75
|
03 Apr 2024
|
8.75
|
30 Mar 2024
|
8.75
|
22 Mar 2024
|
8.75
|
18 Mar 2024
|
8.75
|
15 Mar 2024
|
8.75
|
12 Mar 2024
|
8.75
|
11 Mar 2024
|
8.75
|
09 Mar 2024
|
8.75
|
07 Mar 2024
|
8.75
|
01 Mar 2024
|
8.75
|
29 Feb 2024
|
8.75
|
27 Feb 2024
|
8.75
|
22 Feb 2024
|
8.75
|
21 Feb 2024
|
8.75
|
20 Feb 2024
|
8.75
|
15 Feb 2024
|
8.75
|
14 Feb 2024
|
8.75
|
13 Feb 2024
|
8.75
|
09 Feb 2024
|
8.75
|
08 Feb 2024
|
8.75
|
07 Feb 2024
|
8.75
|
06 Feb 2024
|
8.75
|
05 Feb 2024
|
8.75
|
01 Feb 2024
|
8.75
|